Kala Pharmaceuticals Inc
NASDAQ:KALA

Watchlist Manager
Kala Pharmaceuticals Inc Logo
Kala Pharmaceuticals Inc
NASDAQ:KALA
Watchlist
Price: 0.665 USD 0.99% Market Closed
Market Cap: 14.6m USD

Relative Value

There is not enough data to reliably calculate the relative value of KALA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KALA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
30
Median 3Y
0
Median 5Y
38.9
Industry
2.6
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-4.2
Industry
21.4
Forward
-0.3
vs History
vs Industry
Median 3Y
-5
Median 5Y
-5.2
Industry
16.4
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.9
Industry
22.8
vs History
80
vs Industry
11
Median 3Y
16.4
Median 5Y
18.3
Industry
2.2
vs History
vs Industry
84
Median 3Y
0
Median 5Y
21.6
Industry
2.9
vs History
vs Industry
86
Median 3Y
0
Median 5Y
69.9
Industry
5.5
vs History
1
vs Industry
54
Median 3Y
-2.9
Median 5Y
-3.3
Industry
13
vs History
1
vs Industry
51
Median 3Y
-2.8
Median 5Y
-3.3
Industry
16.5
Forward
0.3
vs History
1
vs Industry
54
Median 3Y
-3.6
Median 5Y
-4.4
Industry
15.6
vs History
1
vs Industry
41
Median 3Y
-3.6
Median 5Y
-4.4
Industry
18.7
vs History
vs Industry
30
Median 3Y
26.5
Median 5Y
29.2
Industry
1.9

Multiples Across Competitors

KALA Competitors Multiples
Kala Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Kala Pharmaceuticals Inc
NASDAQ:KALA
14.6m USD 0 -0.4 0.3 0.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.9 38.1 40.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.3B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.3B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
220.6B GBP 5.1 31.6 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
270.1B USD 4.2 14.2 10.1 11.9
CH
Novartis AG
SIX:NOVN
218B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.7 10.9 12.7
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
Kala Pharmaceuticals Inc
NASDAQ:KALA
Average P/E: 25.1
Negative Multiple: -0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.9
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Kala Pharmaceuticals Inc
NASDAQ:KALA
Average EV/EBITDA: 400.1
0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Kala Pharmaceuticals Inc
NASDAQ:KALA
Average EV/EBIT: 1 712.5
0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5